Faecal calprotectin in term and preterm neonates

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 5, 2010, Pages 542-547

  Kapel, Nathalie ^b   Campeotto, Florence ^c   Kalach, Nicolas ^c   Baldassare, Mariella ^d   Butel, Marie José ^a   Dupont, Christophe ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c University of Bari Policlinic Hospital ^*  (France)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

digestive distress; faecal calprotectin; neonate; preterm

Indexed keywords

CALGRANULIN;

BIRTH WEIGHT; DATA BASE; DIGESTIVE SYSTEM MALFORMATION; DISEASE MARKER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; HUMAN; NEWBORN SCREENING; PREMATURITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REFERENCE VALUE; REVIEW; TERM BIRTH;

FECES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTESTINAL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; NEONATAL SCREENING;

EID: 78149284694     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181e2ad72     Document Type: Review

References (50)

1. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62.
2. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47: 506-13.
3. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem 1983;134:1-6.
4. Brandtzaeg P, Dale I, Fagerhol MK. Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. II. Normal and aberrant occurrence in various epithelia. Am J Clin Pathol 1987;87:700-7.
5. Striz I, Trebichavsky I. Calprotectin\a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004;53:245-53.
6. Bhardwaj RS, Zotz C, Zwaldo-Klarwasser G, et al. The calcium-binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions. Eur J Immunol 1992;22:1891-7.
7. Kligman D, Hilt DC. The S100 protein family. Trends Biochem Sci 1988;13:437-43.
8. Lewit-Bentley A, Rety S. EF-hand calcium-binding proteins. Curr Opin Struct Biol 2000;10:637-43.
9. Loomans HJ, Hahn BL, Li QQ, et al. Histidine-based zinc-binding sequences and the antimicrobial activity of calprotectin. Infect Dis 1998;177:812-4.
10. Steinbakk M, Naess-Andresen CF, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763-5.
11. Boussac M, Garin J. Calcium-dependent secretion in human neutro-phils: a proteomic approach. Electophoresis 2000;21:665-72.
12. Rammes S, Kewitz G, Versmold H, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin dependent pathway. Pediatr Allergy Immunol 1997;8:153-5.
13. Voganasti A, Panyutich A, Miyasaki KT, et al. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 2001;70:130-4.
14. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000;356:1783-4.
15. Poullis A, Foster R, Northfield TC, et al. Faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:675-81.
16. 111Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985; 26:955-60.
17. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a gran-ulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastoenterol 1999;34:50-4.
18. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Digest Liver Dis 2009;41:56-66.
19. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neu-trophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
20. Naess-Andresen CF, Egelandsdal B, Fagerhol MK. Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein). Clin Mol Pathol 1995;48:M278-84.
21. Ton H, Brandsnes O, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54.
22. Fagerberg UL, Lööf L, Merzoug RD, et al. Faecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastro-enterol Nutr 2003;37:468-72.
23. Verstergaard TA, Nielsen SL, Dahlerup JF, et al. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343-7.
24. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008;46:1275-80.
25. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985-92.
26. Shastri Y, Povse N, Stein J. Prospective comparative study for new rapid bedside fecal calprotectin test with an established ELISA to assess intestinal inflammation. Clin Lab 2009;55:53-5.
27. Mohan R, Koebnick C, Schildt J, et al. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 2008;64: 418-22.
28. Golden B, Bunn S, Main M. Age-dependent variations in fecal calpro-tectin concentrations in children. J Pediat Gastroenterol Nutr 2002;34: 324-5.
29. Carroll D, Corfield A, Spicer R, et al. Faecal calprotectin concentrations and diagnosis of necrotizing enterocolitis. Lancet 2003;361:310-1.
30. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastoenterol Nutr 2002;34: 323-5.
31. Nissen AC, Van Girls CE, Van den Neucker A, et al. Faecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr 2004; 38:107-8.
32. Campeotto F, Butel MJ, Kalach N, et al. High faecal calprotectin concentrations in newborn infants. Arch Dis Child Fetal Neonatal 2004;89:F353-355.
33. Baldassarre ME, Altomare MA, Fanelli M, et al. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr, Metab Immun Disord Drug Targets 2007;7:1-5.
34. Savino F, Castagno E, Calabrese R, et al. High faecal calprotectin levels in healthy, exclusively breast-fed infants. Neonatology 2009;97:299-304.
35. Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002;91:45-50.
36. Laforgia N, Baldassarre E, Piontrelli G, et al. Calprotectin levels in meconium. Acta Paediatr 2003;92:463-6.
37. Dorosko SM, Mackenzie T, Connor RI. Fecal calprotectin concentrations are higher in exclusively breastfed infants compared to those who are mixed-fed. Breastfeed Med 2008;3:117-9.
38. Rhoads JM, Fatheree NY, Norori J, et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J Pediatr 2009; 155:823-8.
39. Baldassare ME, Laforgia N, Fanelli M, et al. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolysed formula alone. J Pediatr 2010;156:397-401.
40. Josefsson S, Bunn SK, Domellöf M. Fecal calprotectin in very low birth weight infants. J Pediatr Gastroenterol Nutr 2007;44:407-13.
41. Campeotto F, Kalach N, Lapillonne A, et al. Time course of faecal calprotectin in preterm newborns during the first month of life. Acta Paediatr 2007;96:1531-3.
42. Campeotto F, Baldassarre M, Butel MJ, et al. Fecal calprotectin: cut-off values for identifying intestinal distress in preterm infants. J Pediatr Gastroenterol Nutr 2009;48:507-10.
43. Yang Q, Smith PB, Goldberg RN, et al. Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life. Neonatology 2008;94:267-71.
44. Rougé C, Piloquet H, Butel MJ, et al. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2009;89: 1828-35.
45. Björkström MV, Hall L, Söderlund S, et al. Intestinal flora in very low-birth weight infants. Acta Paediatr 2009;98:1762-7.
46. Walker WA. Gastrointestinal host defence: importance of gut closure in control of macromolecular transport. Ciba Found Symp 1979:201-219.
47. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:64-9.
48. Van Elburg RM, Fetter WP, Bunkers CM, et al. Intestinal permeability in relation to birth weight and gestational and postnatal age. Arch Dis Child Fetal Neonatal 2003;88:52-5.
49. Splichal I, Fagerhol MK, Trebichavsky I, et al. The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages. Immunobiol-ogy 2005;209:681-7.
50. Kapel N, Roman C, Caldari D, et al. Fecal tumor necrosis a and calprotectin as differential diagnostic markers for severe diarrhea of small infants. J Pediatr Gastroenterol Nutr 2005;41:396-400.